C - Chemistry – Metallurgy – 07 – H
Patent
C - Chemistry, Metallurgy
07
H
C07H 21/04 (2006.01) A61K 48/00 (2006.01) C07K 14/47 (2006.01) C12N 15/11 (2006.01) C12N 15/85 (2006.01) C12Q 1/68 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2421087
Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the human prostate cancer LNCaP tumor model in vitro andin vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effectie amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.
L'invention porte sur des compositions et un procédé de traitement de tumeurs de la prostate et autres tumeurs endocrines chez les mammifères dont les humains, par administration d'un oligodésoxynucléotide (ODN) antisens complémentaire d'une partie du gène codant pour l'IGFBP-2. En utilisant in vitro et in vivo le modèle de tumeur humaine LNCaP on a constaté que l'administration de cet ODN réduisait la prolifération des cellules tumorales et aussi le retard de la progression vers l'indépendance vis à vis des androgènes. On a ainsi pu obtenir chez les mammifères dont l'homme un traitement du cancer de la prostate et d'autres cancers à dépendance hormonale, et un retard de la progression des tumeurs de la prostate vers l'indépendance vis à vis des hormones, par administration de doses à efficacité thérapeutique d'un oligodésoxynucléotide (ODN) antisens, complémentaire d'une partie du gène codant pour l'IGFBP-2, et qui abaisse la teneur en IGFBP-2 dans les cellules traitées.
Gleave Martin
Nelson Colleen
Rennie Paul S.
Satoshi Kiyama
Smart & Biggar
The University Of British Columbia
LandOfFree
Antisense insulin-like growth factor binding protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense insulin-like growth factor binding protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense insulin-like growth factor binding protein... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1884036